Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 161Lymphoid 109Other hematologic neoplasm 21Myeloid 5Gastrointestinal 3Dermatologic 3CNS 3Sarcoma 2Classical hematology 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 144pembrolizumab 118Carboplatin 109Bevacizumab 93Cisplatin 65Specimen Handling 63olaparib 52Magnetic Resonance Spectroscopy 52Gemcitabine 41Nivolumab 37Biopsy 36Taxes 35liposomal doxorubicin 34Cyclophosphamide 30Blood Specimen Collection 30niraparib 27Doxorubicin 27lenvatinib 26Topotecan 26Letrozole 25Immunoglobulin G 24Drug Therapy 24Disulfides 22Brachytherapy 22atezolizumab 21Radiotherapy 21fludarabine 20durvalumab 19dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lenalidomide × Gynecologic × 1 year × Clear all
NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡